
1. Nat Commun. 2021 Nov 4;12(1):6393. doi: 10.1038/s41467-021-26744-4.

Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and 
non-human primates.

Costa-Verdera H(#)(1)(2)(3), Collaud F(#)(1)(2), Riling CR(#)(4), Sellier
P(1)(2), Nordin JML(4), Preston GM(4), Cagin U(1)(2), Fabregue J(1)(2), Barral
S(1)(2), Moya-Nilges M(5), Krijnse-Locker J(5), van Wittenberghe L(1), Daniele
N(1), Gjata B(1), Cosette J(1), Abad C(6), Simon-Sola M(1)(2), Charles S(1)(2),
Li M(4), Crosariol M(4), Antrilli T(4), Quinn WJ 3rd(4), Gross DA(1)(2), Boyer
O(6), Anguela XM(4), Armour SM(4), Colella P(1)(2), Ronzitti G(1)(2), Mingozzi
F(7)(8)(9)(10).

Author information: 
(1)Genethon, 91000, Evry, France.
(2)Université Paris-Saclay, Univ Evry, Inserm, Integrare research Unit UMR_S951, 
91000, Evry, France.
(3)Sorbonne University Paris and INSERM U974, 75013, Paris, France.
(4)Spark Therapeutics, Philadelphia, PA, 19104, USA.
(5)Pasteur Institute, 75015, Paris, France.
(6)Université de Rouen Normandie-IRIB, 76183, Rouen, France.
(7)Genethon, 91000, Evry, France. Federico.mingozzi@sparktx.com.
(8)Université Paris-Saclay, Univ Evry, Inserm, Integrare research Unit UMR_S951, 
91000, Evry, France. Federico.mingozzi@sparktx.com.
(9)Sorbonne University Paris and INSERM U974, 75013, Paris, France.
Federico.mingozzi@sparktx.com.
(10)Spark Therapeutics, Philadelphia, PA, 19104, USA.
Federico.mingozzi@sparktx.com.
(#)Contributed equally

Pompe disease (PD) is a severe neuromuscular disorder caused by deficiency of the
lysosomal enzyme acid alpha-glucosidase (GAA). PD is currently treated with
enzyme replacement therapy (ERT) with intravenous infusions of recombinant human 
GAA (rhGAA). Although the introduction of ERT represents a breakthrough in the
management of PD, the approach suffers from several shortcomings. Here, we
developed a mouse model of PD to compare the efficacy of hepatic gene transfer
with adeno-associated virus (AAV) vectors expressing secretable GAA with
long-term ERT. Liver expression of GAA results in enhanced pharmacokinetics and
uptake of the enzyme in peripheral tissues compared to ERT. Combination of gene
transfer with pharmacological chaperones boosts GAA bioavailability, resulting in
improved rescue of the PD phenotype. Scale-up of hepatic gene transfer to
non-human primates also successfully results in enzyme secretion in blood and
uptake in key target tissues, supporting the ongoing clinical translation of the 
approach.

© 2021. The Author(s).

DOI: 10.1038/s41467-021-26744-4 
PMCID: PMC8568898
PMID: 34737297 

